VanEck Healthcare TruSector ETF
TRUH - ETF AI Analysis
Top Page
VanEck Healthcare TruSector ETF (TRUH)
TRUH, the VanEck Healthcare TruSector ETF, is supported by several high-quality healthcare leaders, with major positions in Merck and Johnson & Johnson providing strong financial performance, attractive valuations, and positive growth outlooks that lift the fund’s overall quality. Additional large holdings like Eli Lilly, UnitedHealth, and Amgen add to the strength through solid earnings and strategic initiatives, though issues such as high leverage, cash flow challenges, and valuation concerns in some names can temper the upside. The main risk factor is the ETF’s concentrated exposure to the healthcare sector, meaning regulatory changes, reimbursement pressures, or product-specific setbacks could impact many holdings at once.
TRUH vs. SPDR S&P 500 ETF (SPY)
- AUM
- 607.73K
- Region
- North America
- Expense Ratio
- 0.10%
- Beta
- -0.34
- Issuer
- VanEck
- Inception Date
- Apr 01, 2026
- Dividend Yield
- 0.65%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
TRUH Summary
The VanEck Healthcare TruSector ETF (TRUH) is a U.S. health care fund that invests across the full medical landscape, including drug makers, biotech firms, medical device companies, and health care service providers. It doesn’t track a single index; instead, managers actively pick and adjust holdings based on research and industry trends. Well-known companies like Eli Lilly and Johnson & Johnson are among its largest positions. Investors might consider TRUH for focused exposure to long-term growth from medical innovation and the steady demand for health care. A key risk is that it is heavily concentrated in one sector, so its value can rise or fall with changes in the health care industry.
How much will it cost me?
This ETF has an expense ratio of 0.10%, which means you’ll pay about $1 per year for every $1,000 you invest. That’s lower than the average ETF because, despite being actively managed, it’s priced more like a low-cost fund, helping keep your ongoing costs relatively small.
What would affect this ETF?
This U.S. health care ETF could benefit if medical innovation, an aging population, and steady demand for drugs, devices, and health services support growth at major holdings like Eli Lilly, Johnson & Johnson, and UnitedHealth, especially if the economy slows and investors favor more defensive sectors. On the other hand, tighter drug pricing rules, changes to government health programs, or weaker results from big pharmaceutical and biotech companies could hurt returns, and its focus on a single U.S. sector means it may be more volatile than a broadly diversified fund.
TRUH Top 10 Holdings
TRUH is essentially a U.S. health care pure play, with the story dominated by Big Pharma and biotech heavyweights. Eli Lilly sits in the driver’s seat, rising on the back of blockbuster drug momentum, while Johnson & Johnson and AbbVie add steady, blue-chip strength. Amgen and Gilead are also climbing, giving the fund a solid growth tilt within the sector. On the flip side, Merck’s recent wobble and Abbott’s lagging share price act as mild headwinds. Overall, performance hinges on a concentrated group of large U.S. drug and life-science names.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co | 16.82% | $166.15K | $1.35T | 45.38% | 72Outperform |
 JNJ | Johnson & Johnson | 9.89% | $97.71K | $675.92B | 44.67% | 78Outperform |
 ABBV | AbbVie | 7.59% | $74.94K | $519.48B | 31.00% | 66Neutral |
 MRK | Merck & Company | 5.34% | $52.71K | $364.98B | 61.83% | 80Outperform |
 UNH | UnitedHealth | 5.29% | $52.26K | $363.00B | 23.05% | 72Outperform |
 TMO | Thermo Fisher | 3.93% | $38.78K | $266.10B | 22.37% | 72Outperform |
 AMGN | Amgen | 3.67% | $36.29K | $251.65B | 38.31% | 77Outperform |
 GILD | Gilead Sciences | 3.10% | $30.59K | $211.94B | 38.49% | 78Outperform |
 ABT | Abbott Laboratories | 2.80% | $27.61K | $191.31B | -13.94% | 73Outperform |
 PFE | Pfizer | 2.45% | $24.16K | $167.35B | 15.44% | 74Outperform |
TRUH Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TRUH, the sentiment is Positive. The current price of 32.97 is above the 20-day moving average (MA) of 31.83, above the 50-day MA of 30.39, and compared to the 200-day MA of , indicating a neutral trend. The MACD of 0.74 indicates Negative momentum. The RSI at 69.06 is Neutral, neither overbought nor oversold. The STOCH value of 66.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TRUH.
TRUH Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| TRUH | $32.97 | $36.00(9.20% Upside) | $607.73K | 0.10% | 73Outperform |
 PSR | $104.45 | $115.92(10.98% Upside) | $59.58M | 0.35% | 69Neutral |
 REIT | $30.16 | $33.40(10.73% Upside) | $58.19M | 0.68% | 68Neutral |
 GABF | $45.09 | $51.96(15.25% Upside) | $51.75M | 1.24% | 66Neutral |
 SEMI | $35.20 | $48.61(38.10% Upside) | $40.14M | 0.75% | 75Outperform |
 FPWR | $37.30 | $41.15(10.31% Upside) | $33.47M | 0.96% | 66Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TRUH | VanEck Healthcare TruSector ETF | 32.97 | 7.57 | 29.80% | |
| PSR | Invesco Active U.S. Real Estate Fund | 104.45 | 15.80 | 17.82% | |
| REIT | ALPS Active REIT ETF | 30.16 | 4.51 | 17.59% | |
| GABF | Gabelli Financial Services Opportunities ETF | 45.09 | 0.06 | 0.14% | |
| SEMI | Columbia Seligman Semiconductor and Technology ETF | 35.20 | 5.03 | 16.68% | |
| FPWR | First Trust Eip Power Solutions Etf | 37.30 | 4.18 | 12.61% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.